Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 19/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2555618 | 1.00 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL20905448 | 1.00 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL15357982 | 0.91 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1468567 | 0.91 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1468568 | 0.91 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1871691 | 0.91 | CCR5 (0.39) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL12347236 | 0.88 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL34474774 | 0.88 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL3813845 | 0.87 | NFKB1 (0.38) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL25260214 | 0.85 | SLC6A2 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-4395892-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118302426-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023244554-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230331696-A1 | SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND PREPARATION METHOD THEREFOR | OCUSUN OPHTHALMIC PHARMACEUTICAL (GUANGZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| WO-2023034812-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034812-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2008041090-A1 | MALANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONIST PYRIDINONES | PFIZER LIMITED (GB) | 2008-04-10 | — | — | WO | disclosed |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | SLC6A4 40/4885SLC6A2 119/4885SLC6A3 14/4885 |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | MCHR1, MCHR2, MC1R | SLC6A4 554/4885SLC6A2 343/4885SLC6A3 383/4885 |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | SLC6A4 3539/4885SLC6A2 4130/4885SLC6A3 4113/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | SLC6A4 40/4885SLC6A2 119/4885SLC6A3 14/4885 |
| US-20230331696-A1 | SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND PREPARATION METHOD THEREFOR | ROCK1, ROCK2, NHERF1 | SLC6A4 1196/4885SLC6A2 1197/4885SLC6A3 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.